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Hypoxia-inducible factor (HIF) is a transcription factor that facilitates cellular adaptation
to hypoxia and ischemia. Long-standing evidence suggests that one isotype of HIF,
HIF-1α, is involved in the pathogenesis of various solid tumors and cardiac diseases.
However, the role of HIF-1α in retina remains poorly understood. HIF-1α has been
recognized as neuroprotective in cerebral ischemia in the past two decades. Additionally,
an increasing number of studies has shown that HIF-1α and its target genes contribute
to retinal neuroprotection. This review will focus on recent advances in the studies
of HIF-1α and its target genes that contribute to retinal neuroprotection. A thorough
understanding of the function of HIF-1α and its target genes may lead to identification of
novel therapeutic targets for treating degenerative retinal diseases including glaucoma,
age-related macular degeneration, diabetic retinopathy, and retinal vein occlusions.
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INTRODUCTION
Hypoxia or ischemia stress is generally harmful for the organism but may become beneficial
under certain circumstances. Reduced oxygenation leads to induction of a number of hypoxia-
responsive genes. The known hypoxia-inducible factor (HIF) targets such as erythropoietin (EPO),
vascular endothelial growth factor (VEGF), heme oxygenase-1 (HO-1), adrenomedullin (ADM),
glucose transporter-1 (Glut-1), etc., exert neuroprotective effects on the central nervous system
(CNS; Harten et al., 2010). For instance, hypoxia preconditioning has been shown to increase
Abbreviations: HIF, Hypoxia-inducible factor; EPO, erythropoietin; VEGF, vascular endothelial growth factor; HO-1, heme
oxygenase-1; ADM, adrenomedullin; Glut-1, glucose transporter-1; CNS, central nervous system; AMD, age-related macular
degeneration; DR, diabetic retinopathy; RVO, retinal vein occlusion; bHLH, helix-loop-helix; PHD, prolyl-hydroxylases; VHL
E3, von Hippel-Lindau E3 ubiquitin ligase; ARNT, aryl hydrocarbon receptor nuclear translocator; HREs, HIF-responsive
elements; EPO-R, EPO receptors; RPE, retinal pigment epithelium; ARE/EpRE, antioxidant/electrophile response elements;
eNOS, endothelial nitric oxide synthase; BRB, blood-retinal barrier; qPCR, quantitative polymerase chain reaction; RGCs,
retinal ganglion cells; rhEPO, recombinant human EPO; AAVs, adeno-associated viruses; IOP, intraocular pressure; BDNF,
brain-derived neurotrophic factor; IGF, insulin-like growth factor; GDNF, glial cell line-derived neurotrophic factor; rMSCs,
rat mesenchymal stem cells; SI, sodium iodate; Nrf2, erythroid 2-related factor; GCL, ganglion cell layer; INL, inner nuclear
layer; CNV, choroid neovascularization; rd1, retinal degeneration 1; ONL, outer nuclear layer; rds, retinal degeneration slow;
TNF-α, tumor necrosis factor-α; IL-1β, interleukin-1β; PDT, photodynamic therapy; PDR, proliferative diabetic retinopathy;
DME, diabetic macular edema; ROS, reactive oxygen species; siRNAs, small interfering RNAs; bFGF, basic fibroblast growth
factor; iNOS, inducible nitric oxide synthase.
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resistance of harmful insults by the brain (Kitagawa et al., 1990;
Glazier et al., 1994; Gidday, 2006). Unlike in the brain, however,
knowledge about the neuroprotective effects of HIF targets in the
retina is limited. The roles of HIF targets in retinal neurogenesis
and function are not well-defined and there is no consensus
on their actual functions in the retina. Retinal degeneration
diseases are the leading causes of blindness worldwide and
some of them are closely related to ischemia (Song et al., 2003;
Zheng et al., 2007; Fulton et al., 2009). Retinal hypoxia is
known as the common pathogenic condition leading to vision
loss, including in diseases like glaucoma, age-related macular
FIGURE 1 | Three-dimensional structures of HIF’s alpha subunits and HIF-1α expression levels in normal human nervous tissues. (A) Schematic
representation of the crystal structures of HIF-1α, HIF-2α, and HIF-3α proteins reported at the Protein Data Bank (PDB) with PDB ID 4H6J, 4GHI, and 4WN5,
respectively (http://www.rcsb.org/pdb/home/home.do). Different structural parts are highlighted in the following colors: magenta: α-helix; yellow: residue in isolated
β-bridge; blue: loop; cyan: hydrogen bounded turn; white: bend. They contain the N-terminus, central region and C-terminus. (B) HIF-1α mRNA expression levels in
normal human nervous tissues (normalized intensities in microarray) reported in Genecards (http://www.genecards.org).
degeneration (AMD), diabetic retinopathy (DR), retinal vein
occlusion (RVO), and some retinal degeneration secondary to
stroke or Alzheimer’s disease (Blanks et al., 1989; Katz et al.,
1989). One isotype of HIF, HIF-1α, is abundantly expressed in
the retina (Figure 1B; Zhu et al., 2013). Under normoxia, HIF-1α
protein is rapidly degraded and its expression is hardly detectable
in the adult retinal tissue (Jewell et al., 2001). Under hypoxia
stress, however, HIF-1α expression is upregulated and the protein
is translocated to the nucleus to stimulate the expression of its
downstream targets (Figure 2). These downstream targets such
as EPO and VEGF, which are produced in a relatively low level
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FIGURE 2 | Pathways of HIF-1α and its target genes involved in retinal neuroprotection. The upper panel in yellow background is the schematic
representation of HIF-1α degradation under normoxia. Note that the undegraded HIF-1α binds with HIF-1β to form the HIF-1α/β complex. The complex binds to
HIF-responsive elements (HREs) in promoters that contain the sequence motif 5′-NCGTG-3′ and triggers transcription of more than 100 downstream genes. VHL:
von Hippel–Lindau tumor suppressor protein (E3 ubiquitin protein ligase). The lower panel in pale blue color represents the HIF-1α target genes and their acting
pathways involved in retinal neuroprotection under hypoxia. Note that five main cellular signaling pathways mediating the effect of neuroprotection are highlighted.
Firstly, EPO binds to EPO-R to promote ERK-1/2 signaling, and then activate the Akt pathway, resulting in cell proliferation, anti-apoptosis, anti-inflammation, and
angiogenesis. Also, it can maintain mitochondrial membrane potential to prevent mitochondrial alteration. In particular, EPO can be pumped outside the cytoplasm,
which leads to the autocrine and paracrine effects that further exert retinal neuroprotection. Secondly, VEGF, which binds to VEGF-R, can achieve the same effects as
EPO through activating ERK-1/2 signaling. Simultaneously, it enhances the MEK-1/2 pathway, promoting angiogenesis and inhibiting caspase-3 to constrain cell
death. Thirdly, the secreted multifunctional peptide ADM mainly plays roles in vasomotor regulation, and acts together with VEGF to promote angiogenesis. Fourthly,
Glut-1 transports glucose to the cytoplasm, allowing normal metabolic activity. Fifthly, HO-1 is degraded by ARE/EpRE elements. While under hypoxia, HO-1 blunts
reactive oxygen species (ROS) production and the toxic effect on mitochondria. More importantly, HO-1 retards retinal injury through the IRS1/PI3K/Akt2 and
Keap1/Nrf2 pathways, which further activate mTOR, upregulate anti-apoptotic proteins, and eliminate ROS.
to stabilize the normal development or integrity of retina, are
increased substantially under hypoxia to accommodate these
alterations. When overexpressed, these target proteins may cause
some ocular diseases. On the other hand, the HIF-1α target
genes such as EPO, HO-1, and Glut-1, have the properties
to promote neurogenesis themselves. Therefore, unraveling the
neuroprotective network of HIF-1α target genes in the retina is
important for understanding the mechanisms underlying ocular
diseases.
HIF-1α AND ITS TARGET GENES ARE
INVOLVED IN THE PATHOPHYSIOLOGICAL
ROLES OF RETINA
In humans, HIF family members include HIF-1, HIF-2, and
HIF-3. They have different roles in hypoxia. HIF-1 triggers the
expression of several genes to promote survival in hypoxia. HIF-
2 regulates other functions such as erythropoietin production
in normoxia or hypoxia (Eckardt and Kurtz, 2005) and
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high-altitude adaptation (Yi et al., 2010; Hanaoka et al., 2012).
HIF-3 is considered to be a negative regulator of hypoxia-
inducible gene expression (Augstein et al., 2011; Heikkila et al.,
2011; Ando et al., 2013). The structures of HIFs and HIF-
1α expression in normal human nervous tissues are shown in
Figure 1. HIF is composed of an alpha (α) and a beta (β) subunit.
The α subunit belongs to the helix-loop-helix (bHLH) family
of transcription factors. Under normoxia, it is hydroxylated
at specific proline residues by HIF prolyl-hydroxylases (PHD),
allowing its recognition and ubiquitination by the von Hippel-
Lindau E3 ubiquitin ligase (VHL E3), which labels it for rapid
degradation by the proteasome (Maxwell et al., 1999). The β
subunit is a constitutively-expressed aryl hydrocarbon receptor
nuclear translocator (ARNT). HIF α and β are constantly being
produced and degraded at aerobic conditions. While under
hypoxemia in the retina, only HIF-1α persists and the HIF-1α/β
complex is translocated to the nucleus, where it binds to HIF-
responsive elements (HREs) and induces the transcription of its
target genes involved in oxygen delivery and energy metabolism
(Figure 2). The target genes regulated byHIF-1α aremainly EPO,
VEGF, HO-1, ADM, and Glut-1.
EPO is the first identified gene related to hypoxia which in
turn led to the discovery of HIF (Semenza and Wang, 1992). It
is a glycoprotein hormone predominately secreted by kidney and
liver to stimulate bone marrow erythrocyte production. EPO and
EPO receptors (EPO-R) are widely expressed in different organs
including brain, spinal cord, retina (mainly retinal pigment
epithelium, RPE), heart, gut, kidney, muscle, lung, and testis
(Erbayraktar et al., 2003; Gassmann et al., 2003; Hernandez
et al., 2006). EPO is the dominant HIF-1α target and acts as an
initial factor to initiate the hypoxia condition as well as works
independently without VEGF to promote neovascularization
(Jaquet et al., 2002; Watanabe et al., 2005). VEGF is a HIF-1α
responsive cytokine and is the primary contributor tomitosis and
the development of abnormal vessel growth and angiogenesis. In
a physiological setting, endogenous VEGF, VEGF-A in particular,
is required for RPE stability as well as maintenance and function
of adult retina neuronal cells, especially the survival of Müller
cells and photoreceptors (Nishijima et al., 2007; Saint-Geniez
et al., 2008). VEGF-associated complications are extensively
described in retinal angiogenesis diseases. VEGF is highly
expressed under hypoxia; its expression leads to retinal vessel
leakage and retinal endothelial cell proliferation and migration,
thereby resulting in neovascularization. Anti-VEGF therapy
(bevacizumab or ranibizumab) is largely prescribed for treatment
of angiogenesis and vessel permeability in wet AMD, DR and
RVO (Moravski et al., 2003; Ray et al., 2004; Nagpal et al., 2007).
HO-1, one target product of HIF-1α, is an antioxidative stress
transcription factor and is regulated by antioxidant/electrophile
response elements (ARE/EpRE) that scavenge heme to iron,
carbon monoxide and biliverdin. HO-1 is also involved in the
vasculature and angiogenesis of tumors, wounds and so on.
ADM is a small, secreted multifunctional peptide expressed in
various organs including the retina (Lopez and Martinez, 2002;
Blom et al., 2012). ADM and its receptor are localized in neural
tissues of the embryo (Montuenga et al., 1997) and are present
throughout the retina of the adult mouse (Blom et al., 2012).
Lack of a functional ADM gene resulted in embryonic lethality
(Caron and Smithies, 2001; Shindo et al., 2001; Iesato et al., 2013).
ADM heterozygous knockout mice exhibited reduced expression
of VEGF and endothelial nitric oxide synthase (eNOS) during
retinal angiogenesis, and ADM blockade reduced pathological
retinal angiogenesis (Iesato et al., 2013). ADM is also involved
in some inflammatory and proliferative ocular diseases whose
pathogenesis is ischemia (Takahashi, 2001; Udono-Fujimori
et al., 2003). Its expression is upregulated in response to hypoxic
preconditioning in the retina (Udono et al., 2001; Thiersch et al.,
2008; Zhu et al., 2008; Ponnaluri et al., 2011). It works together
with VEGF to promote angiogenic effect in ischemia (Iimuro
et al., 2004). Glucose is imperative for normal functioning of
retinal neurons and glial cells as they have high-energy demands.
Glucose entry into the retina is a critical part for retinal normoxia.
Glucose transporter-1 (Glut-1), also known as solute carrier
family 2, is an integral membrane glycoprotein and a sole glucose
transporter between blood and retina (blood-retinal barrier,
BRB). The aerobic glycolysis in the retina is reflected by the
increased blood flow metabolite of Glut-1. Glut-1 is also one
of the several adaptive metabolites including glucolytic enzymes
and pyruvate dehydrogenase kinase, to allow retina to better
respond to the ischemia condition. In cultured Müller glial
cells, quantitative polymerase chain reaction (qPCR) revealed
that Glut-1 mRNA expression was 5.85- and 116-fold greater
than that of Glut-3 and -4, respectively (Hosoya et al., 2008),
suggesting that Glut-1 is a dominant transporter in regulating
glucose utilization.
The expression of HIF-1α target genes and the associated
effects in the retina are presented in Table 1. Their
neuroprotective role in retina, especially in the models of
glaucoma, wet AMD and DR, is highlighted and discussed.
HIF-1α AND ITS TARGET GENES IN
MODELS OF RETINAL GANGLION CELL
DEGENERATION
Retinal ganglion cells (RGCs), located near the inner surface of
the retina, receive visual information from photoreceptors and
convey visual signals to the brain via their axons. Damage to
the optic nerve and RGCs lead to permanent loss of vision.
RGC degeneration models mimic the diseases of glaucoma,
optic neuritis, traumatic optic neuropathy injury, and etc.
HIF-1α was detected in the retina and optic nerve head of
human glaucomatous eyes compared with the control eyes,
and its expression was closely concordant with the location
of visual field defects recorded in these eyes (Tezel and Wax,
2004). These observations provide direct evidence that tissue
hypoxia is present in the retina and optic nerve head of human
glaucomatous eyes, and hypoxic signaling is a component of the
pathogenic mechanisms of glaucomatous neurodegeneration.
The dominant HIF-1α target EPO is well-defined in protecting
against ischemic brain injury in the CNS (Marti et al., 2000;
Ehrenreich et al., 2002; Kretz et al., 2005). In the retina,
endogenous EPO protects neuroretinal function in ischemic
retinopathy. Böcker-Meffert et al. first reported that EPO
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TABLE 1 | Effects of HIF-1α target genes on promoting retinal neuroprotection.
HIF-1α
targets




EPO ↑EPO in RPE than in neuroretina,
↑intravitreal EPO in diabetic patients
than nondiabetic patients
34KD Polycythemia, anti-apoptosis, neurotrophic, angiogenic
effect
Garcia-Ramirez et al., 2008
VEGF-A RPE, retinal capillaries, etc. Monomer: 21KD;
dimer: 42KD
Stimulate vasculogenesis and endothelial cell growth,
promote permeabilization of blood vessels and cell
migration, and inhibit apoptosis
Shima et al., 1995;
Saint-Geniez et al., 2008
HO-1 Müller cells, RPE 32KD Catalyze the degradation of heme, and therefore
produce biliverdin, iron and carbon monoxide. Respond
to oxidative stress, hypoxia, heavy metals, cytokines,
and so on. Promote vasculature and angiogenesis
Choi and Alam, 1996; Kikuchi
et al., 2005; Morse and Choi,
2005
ADM Photoreceptor outer segments, ONL,
Müller and amacrine cell somata in
the INL, and some somata in the GCL
12167KD∼6028.73KD,
varies
Vasodilator, upregulate angiogenesis, increase tolerance
to oxidative stress and hypoxic injury
Blom et al., 2012
Glut-1 RPE, choroidal, iridial and pars
planus, BRB, Müller cell, lens, iris,
photoreceptors
55KD Facilitate the transport of glucose across BRB Nihira et al., 1995




complex, INL in adult retina
17.4KD Wound healing, endothelial cell mitogen, mediate
angiogenesis
Gao and Hollyfield, 1995
iNOS Ganglion cells, INL and glial cells in
diabetic eyes, microglia of the
developing quail retina
150-160KD, divided
into nNOS and eNOS
Synthesis of nitric oxide (NO), NO is a messenger
involved in vasodilatation, neurotransmission,
antimicrobial and anti-tumor activities
Abu El-Asrar et al., 2004;
Sierra et al., 2014
RPE, retinal pigment epithelium; ONL, outer nuclear layer; INL, inner nuclear layer; GCL, ganglion cell layer; BRB, blood-retinal barrier; nNOS, neuronal nitric oxide synthase; eNOS,
endothelial nitric oxide synthase.
↑, increased.
could promote neural outgrowth of axotomized RGCs in a
dose-dependent manner (Böcker-Meffert et al., 2002). Systemic
administration of recombinant human EPO (rhEPO) before or
immediately after retinal ischemia was found to not only reduce
histopathological damage and promote functional recovery in
electroretinography, but also decrease apoptotic neurons (Junk
et al., 2002). Sullivan et al. showed that systemic administration
of adeno-associated viruses (AAVs)–mediated mutant form of
EPO (EPOR76E) preserved RGCs and visual function in DBA/2J
glaucomatous mice. The rescued RGCs retained their axonal
projections within the optic nerve and the hematocrit did
not exceed normal limits (Sullivan et al., 2011). Retrobulbar
administration of EPO also protected RGCs from acute elevated
intraocular pressure (IOP; Zhong et al., 2008) and axotomy (Kilic
et al., 2005). The survival rate of the RGCs 14 days after axotomy
lesion was markedly increased from about 20% to more than 60%
(Kilic et al., 2005), which surpasses the neuroprotection efficacy
of classical neurotrophins, such as brain-derived neurotrophic
factor (BDNF; Klocker et al., 2000), insulin-like growth factor-1
(IGF-1; Kermer et al., 2000) or glial cell line-derived neurotrophic
factor (GDNF; Kilic et al., 2004). Consistent with these notions,
systemic applied recombinant EPO protected EPO-deficient
mice against profound retinal ischemia damage (Mowat et al.,
2012) in RGCs (Junk et al., 2002). And subretinal transplantation
of EPO gene-modified rat mesenchymal stem cells (rMSCs)
worked better than rMSCs alone for sodium iodate (SI)-induced
retinal degeneration in rats (Guan et al., 2013). Taken together,
the neuroprotective role of EPO in RGCs is clear and is
mainly accomplished by its anti-apoptosis (Chung et al., 2009),
neurotrophic, and angiogenic effects.
VEGF, another HIF-1α target, was depicted to have protective
roles for non-vascular cells in various models (Yang and
Cepko, 1996; Coultas et al., 2005; Maharaj and D’Amore, 2007;
Emerich et al., 2010). For instance, some isotypes of VEGF
displayed neuroprotective properties in vitro (Jin et al., 2000).
In vivo studies showed that endogenous VEGF-A165b isoform
exerted neuroprotective effects in response to glutamatergic
excitotoxicity on RGCs during rat retinal ischemia-reperfusion
injury, through activation of VEGFR-2 and MEK1/2 pathways
and inhibition of caspase-3 (Beazley-Long et al., 2013). VEGF-
A promoted glaucomatous RGC survival via VEGFR-2, thereby
highlighting the potential risks associated with using VEGF-A
antagonists in ocular diseases (Foxton et al., 2013). Anti-VEGF
reduced the potential benefit of VEGF in neuroprotection and
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exacerbated RGC apoptosis (Nishijima et al., 2007). Similar
to EPO, VEGF protects axotomized RGCs from degeneration
through ERK1/2 and Akt pathways (Böcker-Meffert et al., 2002;
Kilic et al., 2006). Ischemic preconditioning prior to ischemia-
reperfusion injury showed increased VEGF-A levels. And the
VEGF-A levels substantially decreased in a dose-dependent
manner following RGC apoptosis. Despite the overwhelming
evidence indicating a role for VEGF in neuroretinal protection, a
few groups did not observe any damage to retinal photoreceptors
or RGCs after blocking VEGF or its receptors (Miki et al., 2010;
Sobaci et al., 2013; Demirel et al., 2015). These discrepancies
suggest a possibility that the neuroprotective function exerted
by VEGF may be conditional and context-dependent. Therefore,
further studies to clarify the neurotrophic role of VEGF in RGCs
is warranted.
Oxidative stress is considered to be an early event of various
retinal diseases (Liu et al., 2007). And indeed, HO-1 exerts a
protective effect on ocular diseases. Previous findings suggested
that functional human HO-1 could prevent RGC death in the
adult rat retina after pressure-induced ischemia (Hegazy et al.,
2000). The nuclear factor erythroid 2-related factor (Nrf2)/HO-
1-antioxidant pathway was activated in ischemia-reperfusion-
induced rat retinal damage, and this activation led to better
preservation of ganglion cell layer (GCL) and inner nuclear
layer (INL; Varga et al., 2013; He et al., 2014). Nrf2 and HO-
1 were also increased in attenuated GCL damage following
limb remote ischemic conditioning of the retina (Zhang X.
et al., 2014). Overexpression of HO-1 in RGCs facilitated the
survival of some RGCs for up to 7 days after optic nerve
crush (Himori et al., 2014). AAV-mediated HO-1 gene transfer
(AAV-HO-1) into the vitreous promoted RGC survival following
ischemia/reperfusion-induced damage, while inhibiting HO-1
counteracted the effect in rats (Peng et al., 2008). Stimulation
of Nrf2/HO-1 axis could be of interest for the treatment of
retinal degeneration such as glaucoma, AMD, and DR which
will be discussed below (Foresti et al., 2013, 2015). Furthermore,
increased ADM was found in the vitreous humor of glaucoma
(Evereklioglu et al., 2002), DR (Ito et al., 2003; Shaw et al.,
2006; Weng et al., 2006), uveitis, and vitreoretinal patients
(Udono et al., 2002), and in the plasma of retinitis pigmentosa
individuals (Vingolo et al., 2005). Glucose deprivation may result
in an increased ability to protect RGCs from glutamate-induced
excitotoxicity (Toft-Kehler et al., 2014), but the function of Glut-
1 was not tested in the RGC degeneration models.
The efficacy of HIF-1α and its target genes in protecting
against RGC degeneration may open new perspectives for the
treatment of glaucoma, optic neuritis, and traumatic optic
neuropathy injuries. Developing new treatment targeting on
HIF-1α target genes for RGC degeneration deserves concerted
efforts in the near future.
HIF-1α AND ITS TARGET GENES IN
MODELS OF PHOTORECEPTOR
DEGENERATION AND WET AMD
The pathogenesis of AMD is not well-known. The wet AMD,
also known as neovascular or exudative AMD, causes central
vision loss due to RPE atrophy, neovascularization, and death of
photoreceptors. Oxidative stress was implicated in the senescence
of RPE cells and the pathogenesis of AMD. Development of
choroid neovascularization (CNV), which is mediated mainly
by HIF-1α and VEGF, is the most significant threat for AMD;
therefore, inhibiting HIF-1α and VEGF is often used for treating
AMD. However, it was found that focused activation of HIF
transcription factors in normoxic photoreceptors resulted in a
transient protection of rods against light damage (Lange et al.,
2011). Pyruvate application, which stabilized HIF-1α and HIF-
2α, protected the mouse retina against white light damage (Ren
et al., 2011).
Unlike HIF-1α, the effect of EPO on protecting
photoreceptors and RPE cells is uncontroversial. EPO is
generally regarded as a potent neuroprotective factor for
photoreceptors (Becerra and Amaral, 2002). In the adult
mammalian retina, systemically applied EPO was protective
against light-induced photoreceptor apoptosis (Becerra and
Amaral, 2002; Grimm et al., 2002). It stabilized the retinal
vasculature and inhibited the development of focal vascular
lesions in photoreceptor degeneration (Shen et al., 2014).
Subretinal delivery of EPO protected against light-induced and
genetic photoreceptor degeneration (Zhang et al., 2008; Rex
et al., 2009; Colella et al., 2011; Busch et al., 2014) through the
ERK1/2 and Akt pathway (Shen et al., 2010). An earlier report
revealed that by either transgenic or systemic applications,
EPO protected against apoptotic cell death during acute,
light-induced photoreceptor cell death but not in genetically
based retinal degeneration such as in retinal degeneration
1 (rd1) or dominant retinitis pigmentosa mouse models
(Grimm et al., 2004). Findings from a study demonstrated that
subretinal injection of EPO AAVs resulted in approximately
an 8 µm thicker outer nuclear layer (ONL) in retinas of
retinal degeneration slow (rds) mice compared to the control
group (Hines-Beard et al., 2013). Nevertheless, one may
argue that the neuroprotective effect of EPO is short-lived
and the ONL may degenerate without a repeated hypoxia
preconditioning (Grimm et al., 2005). For RPE cells, EPO,
and EPO-R are highly enriched in light-induced apoptotic
RPE cells (Chung et al., 2009). EPO protected RPE from
oxidative damage by decreasing inflammatory cytokines of
tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β), and
inhibiting caspase-3-like activity (Gawad et al., 2009; Wang et al.,
2009).
Anti-VEGF agents are widely used in the treatment of
choroidal neovascularization for AMD. However, long-term
VEGF inhibition could have deleterious effects on the remaining
healthy retina given the well-documented role of VEGF in
normal development of the retinal vasculature (Hernandez
and Simo, 2012). Non-isoform-specific inhibition of VEGF for
treating angiogenesis can constrain the neuroprotective role of
some isoforms of VEGF and damage retinal and sensory neurons.
Inhibiting VEGF following photodynamic therapy (PDT) which
causes elevated VEGF resulted in photoreceptor apoptosis,
suggesting that VEGF after PDT is neuroprotective (Suzuki et al.,
2011). Depletion of VEGF-A specifically in neural progenitor
cells resulted in thinner retina and aberrant cortex development
(Haigh et al., 2003).
Frontiers in Cellular Neuroscience | www.frontiersin.org 6 February 2017 | Volume 11 | Article 20
Cheng et al. HIF-1α Targets in Retinal Neuroprotection
Expression of HO-1 in RPE is essential for the survival of
photoreceptors (Satarug et al., 2008) and increases following
repetitive hypoxia preconditioning in the retina (Zhu et al.,
2007). HO-1 is also a sensitive marker for light-induced insult
in the retina (Kutty et al., 1995). An increased expression
of HO-1 is thought to be a cytoprotectant against light-
induced oxidative damage in the retina (Kutty et al., 1995).
HO-1 overexpression protected photoreceptors from cellular
damage caused by intense light exposure (Sun et al., 2007)
and protected RPE cells against the toxic effect induced by
high glucose and oxidative/nitrosative stress (Castilho et al.,
2012). RPE cells derived from neovascular AMD patients
displayed much higher HO-1 and HO-2 antigen levels compared
to those from younger individuals, suggesting that HO
has protective mechanisms against oxidation (Frank et al.,
1999).
ADM, another HIF-1α target, is the first
neurotransmitter/neuromodulator found in the RPE (Udono
et al., 2000, 2002). It can promote hypoxia vasodilation in
retinal arteries (Maenhaut et al., 2007). Additionally, ADM
suppressed the migration, proliferation and tube formation
of human RPE cells under hypoxia (Chen et al., 2014).
Administration of ADM in mice inhibited macrophage
migration from RPE to prevent choroidal neovascularization
(Yuda et al., 2012). These results were in agreement with
a neuroprotective role for ADM in ischemic brain injury
(Willis et al., 1996; Dogan et al., 1997; Xia et al., 2004, 2006;
Miyashita et al., 2006; Igarashi et al., 2014; Zhang H. et al.,
2014).
The above evidence suggests that HIF-1α and its target
genes can act as a retinal shield against photoreceptor
degeneration and wet AMD injuries in the retina.
Further studies are required to clarify the role of these
transcription factors in retinal pathology to determine
whether they can be exploited as potential therapeutic
targets in treating photoreceptor degeneration and
wet AMD.
HIF-1α AND ITS TARGET GENES IN
MODELS OF DIABETIC RETINOPATHY
Elevated HIF-1α and VEGF are generally accepted to be
harmful for diabetic retinopathy, despite some studies found
that anti-VEGF in DR rats had detrimental effects on
neuronal cells (RGC, amacrine and bipolar cells) which
are present in the inner layers of the retina (Park et al.,
2014). The situation is different for the HIF-1α targets such
as EPO, HO-1, ADM, and Glut-1. Strikingly high levels
of intravitreal EPO have been found in both proliferative
diabetic retinopathy (PDR) and diabetic macular edema (DME)
patients (Hernandez et al., 2006). EPO-R is upregulated
in DR neurosensory retina in response to diabetic stress
(Junk et al., 2002; Zhang et al., 2008). The upregulation
of EPO/EPO-R leads to a maintenance-survival mechanism
thereby adapting to insulin increase in early DR. Intravitreal
injection of EPO induced downregulation of EPO-R, VEGF, and
VEGF receptor in streptozocin-induced DR rats (Mitsuhashi
et al., 2013). In DR, EPO-derived peptide and EPO helix-B
domain significantly protected against neuroglial and vascular
degeneration without altering hematocrit or exacerbating
neovascularization or thrombosis in diabetic rats (McVicar et al.,
2011). Administering suberythropoietic EPO is also vaso- and
neuro-protective in experimental early DR both in vivo and in
vitro (Zhang et al., 2008; Wang et al., 2011; Mitsuhashi et al.,
2013).
HO-1 was found to be increased in the retina of db/db
DR mice and cultured retinal explants (He et al., 2013).
It was reported that HIF-1α-mediated, long-lasting HO-1
elevation contributed to long-term retinal ischemia tolerance
(Zhu et al., 2007). Induction of HO-1 by compounds or
oxidative stress reduced damage in the retina (Mandal et al.,
2009; Kim et al., 2012; Chao et al., 2013; Rappoport et al.,
2013; Koskela et al., 2014; Lee et al., 2014) and decreased
retinal microvascular complications in DR (Geraldes et al.,
2008) through the IRS1/PI3K/Akt2 pathway (Cukiernik et al.,
2003). Overexpression of HO-1 in the retina restored visual
function in diabetic rat models (Geraldes et al., 2008; Shyong
et al., 2008) and systemic hypoxia mice (Zhu et al., 2007).
Furthermore, diminished HO-1 expression in RPE cells was
found in diabetic patients (da Silva et al., 1997). HO-
1 also exerts anti-inflammatory, anti-apoptotic and anti-
proliferative effects through Nrf2/ERK-related signaling (Peng
et al., 2011; Fan et al., 2012). It could drive the resolution
of inflammation by reducing macrophage infiltration in the
ischemia-reperfusion injured retina (Sun et al., 2010). Other
in vitro experiments supported a similar anti-inflammatory
role for HO-1 (Willis et al., 1996). Inhibition of upregulated
HO-1 in Müller cells resulted in increased infiltration of
inflammatory cells and destruction of the retina in ischemia-
reperfusion injury rats (Ulyanova et al., 2001; Arai-Gaun
et al., 2004). Inhibition of HO-1 also enhanced reactive
oxygen species (ROS) production and the toxic effect (Castilho
et al., 2012). These findings have revealed that HO-1 is
cytoprotective by helping the cells to adapt to the oxidative stress
environment.
For ADM, its plasma level was lower in juvenile type
1 diabetes patients without retinopathy than that in healthy
subjects (Semeran et al., 2013). Glut-1, as indicator of
glucose transportation in the retina, played a big role in the
pathophysiology of DR. In the human and monkey, Glut-1
is diffusely expressed throughout the whole retina, including
the BRB cells, RPE, vascular endothelium, and rod and cone
inner and outer segments (Nihira et al., 1995). Elevated levels
of Glut-1 increased the ability of retina to utilize glucose
for normal metabolic activity (Schubert, 2005). Knockdown
or blockade of Glut-1 by small interfering RNAs (siRNAs)
significantly reduced retinal glucose in diabetic mice (Lu et al.,
2013). In contrast, some studies suggested that inhibiting Glut-
1 could prevent expression of early biomarkers of DR (Lu
et al., 2013) and that Glut-1 was downregulated in oxidative
RPEs (Fernandes et al., 2011). Expression of Glut-1 in the
microvasculature does not account for the glucose accumulation
in diabetic retina (Puchowicz et al., 2004). Therefore, the
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neuroprotective function of Glut-1 in the retina needs to be
further investigated.
DISCUSSION
Some other HIF-1α targets such as basic fibroblast growth factor
(bFGF; Cuevas et al., 1998; Yu et al., 2004; Valter et al., 2005),
inducible nitric oxide synthase (iNOS; Sakamoto et al., 2006; Zhu
et al., 2006; Sun et al., 2010), etc. which are less reported in retinal
neuroprotection are not discussed here. The selected reports of
HIF-1α target genes on retinal neuroprotection are summarized
in Table 2.
HIF-1α together with its target genes are essential for retinal
development, vasculature stability, proper retinal function,
and vision maintenance. Hypoxia pre-conditioning mimics the
physiopathological responses of the retina to provide protection
for neuronal cells. PHD inhibitors stabilize HIF transcription
factors, especially HIF-1α, to mediate genetic adaptation to
hypoxia. Under hypoxia, the neuroprotective effect of HIF-1α
targets might be multimodal, including promotion of oxygen
and glucose supply, neovascularization, antioxidization, anti-
inflammation, anti-apoptosis, and neurotrophy.
Nevertheless, the HIF-1α target gene therapymay be a double-
edged sword (Grimm and Willmann, 2012). High-dose toxicity
and longtime exposure may over-activate HIF-1α and bring
about severe consequences in terms of side effects. Several
lines of evidence have suggested that HIF-1α overexpression
can contribute to retinal pathologies, including retinopathy of
prematurity, DR, AMD, glaucoma, and high altitude retinopathy
(Arjamaa andNikinmaa, 2006;Willmann et al., 2013). It may also
promote neovascularization, oncogenesis, and metastasis. New
method seeking to manipulate the HIF-1α target genes to treat
various ocular diseases as well as to reduce the side effects are
warranted for new therapeutic avenues. Take the dominant HIF-
1α target EPO as an example. Accumulating evidence makes EPO
particularly attractive in preventing retinal degeneration in the
early stages of retinal diseases. However, before applying EPO
for retinal degenerative diseases, two critical points need to be
taken into account. The first is the EPO form. Longtime usage
and overdose of EPO lead to chronic polycythemia, which is a
lethal side effect (Gassmann et al., 2003). Engineering an effective
package for neuroprotective EPO and attenuating erythropoietic
and angiogenic activity is the key for such a therapy. Secondly,
timing and dose are crucial for EPO treatment of retinal
diseases. It has been shown that intraocular delivery of EPO
has a lower efficiency than when administered systemically. This
suggests that hormone systemic effects contribute to progressive
neuroprotection (Colella et al., 2011). Furthermore, high levels
of EPO is not protective due to its bell-shaped dose curve
(Hines-Beard et al., 2013), and the neuroprotective dose is
higher than that required for erythropoiesis (Coleman and
Brines, 2004). Early retinal EPO replenishment improves retinal
vascular stability, but elevated EPO levels during the proliferation
stage contribute to neovascularization and ocular diseases
(Coleman and Brines, 2004; Chen et al., 2008). Therefore,
early administration of EPO at a proper dose for retinal
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degeneration is important, for it can activate endogenous EPO-
R in the affected tissue through stimulation of potent ischemic
preconditioning. The treating course and strategy should be
tailored according to patients’ responses. Continuous delivery of
EPO may lead to elevated local EPO and cause insults. Overall,
timing, dose and route of administration are the important
factors to be considered for balancing favorable vs. detrimental
effects during EPO retinal therapy. Similar problems may be
seen in exploiting other HIF-1α targets for treating retinal
degeneration.
HIF-1α being a “master switch” for regulating all oxygen-
dependent retinal diseases is critical in construction of new
therapeutic avenues for treating retractable retinal insults.
Additional preclinical experiments need to be conducted in
order to elucidate the physiological and neuroprotective role of
HIF-1α targets in the retina. A more refined understanding of
the complex functions of HIF-1α and target genes will help to
manipulate these genes and define new and more-specific targets
for retinal degenerative diseases.
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